Clinical Trial Detail

NCT ID NCT02624700
Title Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Virginia Commonwealth University
Indications

triple-receptor negative breast cancer

Therapies

Pemetrexed Disodium + Sorafenib

Age Groups: adult

Additional content available in CKB BOOST